Lifeline for kids: expanded access to vedolizumab for severe IBD

NCT ID NCT06856135

First seen Mar 02, 2026 · Last updated May 15, 2026 · Updated 15 times

Summary

This program offers continued access to vedolizumab, given as an IV infusion, for children and teenagers with moderate to severe ulcerative colitis or Crohn's disease who completed a prior study and still benefit from the treatment. It is designed for those without suitable alternatives in the U.S. until the drug becomes commercially available. The goal is to maintain disease control and prevent worsening symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Center for Digestive Healthcare

    AVAILABLE

    Atlanta, Georgia, 30342, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seattle Children's Hospital

    AVAILABLE

    Seattle, Washington, 98105, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco

    AVAILABLE

    San Francisco, California, 94158, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.